Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott, Baxter, Bristol-Myers Squibb: Emerging Markets Earnings Roundup (Part 1 of 3)

This article was originally published in PharmAsia News

Executive Summary

A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources in Asia and forming more Asia partnerships. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.

You may also be interested in...



Abbott, Eli Lilly, Novartis: Emerging Markets Earnings Round Up (Part 1)

Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.

Abbott, Eli Lilly, Novartis: Emerging Markets Earnings Round Up (Part 1)

Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.

Emerging Markets Round Up From JP Morgan Healthcare Conference (Part 2 of 2)

[Editor's note: This is part two of a story carrying highlights on emerging markets from the annual JP Morgan Healthcare Conference in San Francisco last week.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel